J&J halts Doribax pneumonia trial on death rate; Jazz looks for 40% rise in Xyrem sales;

@FiercePharma: Watson CEO does about-face, says Pfizer won't keep 40% of Lipitor market. $PFE's share was 41% on Dec. 24--Bloomberg. | Follow @FiercePharma

> Johnson & Johnson ($JNJ) stopped a pneumonia trial of its antibiotic Doribax, which is FDA-approved for abdominal and urinary infections, after more Doribax patients died. News

> Jazz Pharmaceuticals ($JAZZ) says it expects a larger profit this year, thanks to the completion of its Azur Pharma buyout and fast-growing sales of its narcolepsy drug Xyrem. Report

> Physicians Interactive Holdings attracted a $17 million investment from Merck's Global Health Innovation Fund to back key products comprising clinical reference tools, electronic drug sampling and interactive education. Release

> Norgine is laying off three dozen workers at a facility in Wales, or 9% of its local workforce, because of declining demand for products. Story

> Lens maker Essilor bought a majority stake of a lab based in California and inked deals in Africa and South America. Article

Biotech News

@FierceBiotech: Bloomberg: Amgen May Join Gilead as Biotechs Seek Acquisitions to Grow. Article | Follow @FierceBiotech

@JohnCFierce: Bloomberg piece makes spike in drug approvals a sign of underlying shift; Really? I'm not so sure. More | Follow @JohnCFierce

@RyanMFierce: BioDelivery Sciences ($BDSI) grabbed $30M upfront from Endo Pharma for license to pain drug. Release | Follow @RyanMFierce

@FierceMedDev: BBC News: Headache sufferer 'abandoned' after electrode treatment. Story | Follow @FierceMedDev

@MaureenFierce: J&J AIDS vaccine helps protect monkeys from virus in study. Item | Follow @MaureenFierce

> Exclusive: MIT's Langer, Farokhzad launch combination-med biotech. News

> Xoma axing 84 jobs to save dollars for lead drug. More

> BioDelivery Sciences shares spike on $180M pain drug deal with Endo Pharma. Article

> Amgen, big biotechs poised for big year of deals, analysts say. Story

And Finally... Weekend plans with the significant other? A new study found greater-than-previously-thought personality differences between males and females. Item

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.